DIFFEREN TIATION BETWEEN PROSTATIC\' C A RCINOMA A ND BENIGN PROSTATIC HYPERPLASIA BY AgNOR STAINING

Authors

  • PARVIN KHERADMAND
  • SIMIN TORABI-NEZHAD From the Department of Pathology, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, IR. Iran.
Abstract:

Thirty cases of benign prostatic hyperplasia and 30 cases of prostatic adenocarcinoma were selected and stained by AgNOR (argyrophilic staining of the nucleolar organizer region) method. Specimens were obtained by either prostatectomy (open!TIJR) or needle biopsy of the prostate. In this study, the sections of prostatic adenocarcinoma were reviewed. 6 cases were diagnosed as well-differentiated, 12 cases as moderately-differentiated and 12 cases as poorly differentiated adenocarcinoma. The method of AgNOR staining was applied to see if it would be useful in the distinction between benign and malignant lesions. In benign lesions, the mean number of AgNOR count was 2.5 and in malignant specimens was 7.4. Prostatic hyperplasia (benign) specimens showed two or three well-defined NORs, but in malignant tumors, there were many irregular small NORs. AgNOR stain can be used for differentiation between benign and malignant lesions of the prostate, but this stain should not be used as a reliable index for grading prostatic adenocarcinoma, because overlapping was seen in some cases.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

differen tiation between prostatic' c a rcinoma a nd benign prostatic hyperplasia by agnor staining

thirty cases of benign prostatic hyperplasia and 30 cases of prostatic adenocarcinoma were selected and stained by agnor (argyrophilic staining of the nucleolar organizer region) method. specimens were obtained by either prostatectomy (open!tijr) or needle biopsy of the prostate. in this study, the sections of prostatic adenocarcinoma were reviewed. 6 cases were diagnosed as well-differentiated...

full text

Benign prostatic hyperplasia.

This article reviews the epidemiology of benign prostatic hyperplasia (BPH), evaluation of patients with lower urinary tract symptomatology (LUTS), and management of patients with BPH and LUTS. The evaluation includes history and physical examination, laboratory testing, and specialized studies. The management includes medical and surgical options. Medical options include alpha-1-adrenergic rec...

full text

Benign Prostatic Hyperplasia

Urinary obstruction as a result of benign prostatic disease has probably been recognized to some degree since the earl iest days of medicine. This association was probably f irst formalized by Riolan in the seventeenth century. In the mideighteenth century, Morgagni (248) provided one of the earl iest descriptions of BPH and enumerated many of the potential medical problems attendant to its dev...

full text

Benign Prostatic Hyperplasia (bph)

Comprehensive studies show that the holmium laser is ideal for treating BPH. Holmium laser treatments have been the most rigorously investigated BPH techniques. Over 90 articles have been published from 8 randomized clinical trials and over 30 case studies and comparative series. The American, European, British and Australasian urology associations recommend holmium laser for BPH treatment. Hol...

full text

Benign prostatic hyperplasia

Benign prostatic hyperplasia (BPH; Pic. 1) is characterized by increased size of the prostate leading to difficulties with passing the urine. The cells of prostate may increase in numbers (hyperplasia) or in size (hypertrophy) resulting in larger size of prostate. As result, prostatic nodules form in the transition zone of the prostate, which is the area where the prostate is surrounding the ur...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 12  issue 4

pages  333- 338

publication date 1999-02

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023